Headlines about Sierra Oncology (NASDAQ:SRRA) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sierra Oncology earned a daily sentiment score of 0.03 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.7765045500986 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:
- Do SMAs Signal a Trend Reversal? – Sierra Oncology, Inc. (NASDAQ: SRRA) – The Investor Guide (wallstreetnews24.com)
- Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York – PR Newswire (press release) (prnewswire.com)
- Late-Breaking Abstract Reporting SRA737 Preclinical Activity in – KAIT Jonesboro, AR – Region 8 News, weather, sports (kait8.com)
Separately, Zacks Investment Research cut Sierra Oncology from a “hold” rating to a “sell” rating in a research report on Friday, March 2nd.
Sierra Oncology (NASDAQ:SRRA) last issued its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. During the same period in the previous year, the company earned ($0.30) EPS. research analysts predict that Sierra Oncology will post -0.87 earnings per share for the current fiscal year.
Sierra Oncology Company Profile
Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.